Wednesday, May 22, 2024 IND242 substudy AThe IND.242 substudy A: A phase II study of neoadjuvant JDQ443 KRAS G12C inhibitor in patients with surgically resectable non-small cell lung cancer (NSCLC) is closed to accrual. Although accrual is now closed to this substudy, treatment and follow up of patients will continue according to the protocol. Please note the IND.242 main study remains open. GCC1 trialThe GCC1 trial (SWOG S1823) - A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumours has closed to further accrual having met the accrual target with 964 study participants enrolled. Canadian sites contributed 23 percent of the total accrual, represented the highest accruing site overall, and had three sites in the top 10.
